YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

eCliniqua Briefs – Nov. 17, 2008

Tripos International, a provider of drug discovery informatics products and services, has completed the acquisition of Pharsight Corporation, a provider of software, strategic and regulatory services designed to optimize clinical drug development. The transaction, valued at approximately $57 million, moves Pharsight into the Tripos portfolio. more 

Nextrials' lagship electronic data capture and clinical trial management software, Prism, has captured a Gold Mobile Star Award from MobileVillage, the 15-year leader in market development and news services about mobile technology. Prism was a winner in the enterprise software category for healthcare data capture. more 

Medidata Solutions announced that one of the largest contract research organizations in Japan, CMIC, has joined Medidata’s ASPire to Win partnership program. CMIC will incorporate Medidata Rave platform into its existing offerings to manage electronic clinical trial data for biopharmaceutical and medical device companies around the world. more 

Octagon Research Solutions released itsViewPointQuantum platform, which is the foundation for the ViewPoint Quantum environment, which provides management and control of complex processes across the R&D enterprise. The launch of the platform will be followed by subsequent releases of business modules that provide functionality to support submission standards such as eCTD (electronic Common Technical Document) and CDISC (Clinical Data Interchange Standards Consortium) and complex activities relating to these standards such as global submission publishing, compilation and lifecycle management. more 

Synexus recently randomized more than 1300 patients in a vaccine study at five sites across Europe over a three-week period, as part of a global program. The Synexus sites were the first to achieve its upwardly revised target due to a sophisticated patient recruitment operation. In the vaccine study Synexus’ huge database of patients wanting to take part in a clinical study was an important component. more 

ACORN CRO, a contract research organization exclusively focused on oncology, announced that its third quarter had once again exceeded projections as the company continues to experience banner growth.  “The industry has responded favorably to ACORN's ability to consistently exceed client expectations, and we are ahead of projections in both number of projects, patients accrued, and revenue generated,” said Steve Coplon, ACORN CEO.

View Next Related Story
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.